In a pooled analysis of 5 studies, men with BRCA1 mutated prostate cancer compared to BRCA2 mutated had a lower PSA50 response rate (23.8% vs. 65.2%), lower overall response rate (26.3% vs. 50%) and a lower median radiographic progression-free survival (4.1 months vs. 10.1 months) (3). This evidence concerns the gene BRCA2 and prostate carcinoma.